drugset / Trial / NCT00577668
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
Non-randomizedSingle-groupOpen-labelPrevention
Summary
In this study, researchers want to find out if using the VTD regimen, along with higher doses melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be given safely to subjects who have failed previous transplant(s).
Timeline
- Start
- 2007-04
- Primary completion
- 2009-04
- Completion
- 2009-04
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Melphalan | Small molecule | 100 mg/m2 | — |
| Subject | Thalidomide | Other / unclassified | 200 mg | — |